CJC-1295 & Ipamorelin Blend Research Peptide — Synergistic Growth Hormone Secretagogue Formulation for Laboratory Use

Product Overview

The CJC-1295 & Ipamorelin Blend is a research-grade synergistic peptide combination combining two complementary growth hormone secretagogues in a single lyophilized formulation. It is supplied as a sterile lyophilized powder in sealed vials. Each package contains ten vials, with each vial containing 5mg of CJC-1295 and 5mg of Ipamorelin (total 10mg). This product is manufactured exclusively for scientific investigation and in vitro laboratory experimentation.

Key Specifications at a Glance:

• Quantity: 10 vials per pack

• Composition: CJC-1295 (5mg), Ipamorelin (5mg)

• Total per vial: 10mg

• Form: Lyophilized (freeze-dried) powder

• Purity: >99% verified by third-party testing

• Research Focus: Growth hormone axis modulation, GHRH and GHSR pathways

• Research Use Only: Not for human or animal consumption

Understanding the CJC-1295 & Ipamorelin Blend: The Research Context

The CJC-1295 & Ipamorelin Blend combines two distinct classes of growth hormone secretagogues that work through complementary mechanisms. This dual-pathway approach allows researchers to study the growth hormone axis from multiple angles simultaneously. CJC-1295 & Ipamorelin Blend

The Two Components of the Blend:

The Complementary Pathways:
Growth hormone secretion from the pituitary is regulated by two primary hypothalamic signals:

• Growth Hormone-Releasing Hormone (GHRH): Stimulates growth hormone synthesis and release through GHRH receptors (GHRHR)

• Ghrelin (via GHSR): Amplifies growth hormone release through growth hormone secretagogue receptors (GHSR)

CJC-1295 mimics GHRH, while Ipamorelin mimics ghrelin’s growth hormone-releasing effects without its other metabolic effects. By combining these two pathways, the blend allows researchers to study the integrated regulation of the growth hormone axis.

Third-Party Testing and Quality Assurance

Every batch of the CJC-1295 & Ipamorelin Blend undergoes rigorous independent analytical testing to verify identity, purity, and consistency. This third-party testing ensures that researchers receive a product that meets strict quality specifications before it is approved for release.

The testing process includes:

• Identity verification through mass spectrometry for both peptides

• Purity analysis using high-performance liquid chromatography (HPLC)

• Batch-to-batch consistency checks

• Residual solvent analysis to confirm complete lyophilization

With a verified purity exceeding 99%, this blend meets the high standards required for serious laboratory research applications. Each vial contains only the lyophilized research compound combination with no unnecessary additives, fillers, or excipients.

Component Profiles: The Two Peptides

CJC-1295 (5mg) — The GHRH Analog for Sustained GHRHR Activation

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a 30-amino acid peptide modified with a reactive lysine group for enhanced stability.

Key Research Interests:

• GHRH receptor (GHRHR) activation and signaling

• Growth hormone synthesis and secretion studies

• Pituitary somatotroph function

• Prolonged receptor activation kinetics

Structural Features of CJC-1295:

• 30-amino acid synthetic peptide

• Modified with a reactive lysine group

• Enhanced resistance to enzymatic degradation

• Specifically targets GHRH receptors on pituitary somatotrophs

CJC-1295 functions by binding to and activating GHRH receptors, which are G-protein coupled receptors (GPCRs) on pituitary somatotroph cells. This activation stimulates both the synthesis and pulsatile release of growth hormone.

Ipamorelin (5mg) — The Selective GHSR Agonist

Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue receptor (GHSR) agonist. It was developed as a third-generation growth hormone secretagogue with a distinct selectivity profile. CJC-1295 & Ipamorelin Blend

Key Research Interests:

• GHSR (ghrelin receptor) activation and signaling

• Growth hormone pulse amplitude modulation

• Isolated GH axis activation (minimal off-target effects)

Structural Features of Ipamorelin:

• Pentapeptide (5 amino acids)

• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

• Contains non-standard amino acids (Aib, D-2-Nal, D-Phe)

• Enhanced enzymatic stability

• Selective for GHSR with minimal effects on other pituitary hormones

Ipamorelin functions by binding to growth hormone secretagogue receptors (GHSR), also known as ghrelin receptors. Unlike earlier GHS compounds, Ipamorelin demonstrates high selectivity for growth hormone release with minimal effects on other pituitary hormones such as cortisol and prolactin. CJC-1295 & Ipamorelin Blend

The Synergy: Why Combine CJC-1295 and Ipamorelin?

Single-pathway growth hormone stimulation often produces limited responses due to the complex, redundant regulation of the growth hormone axis. The CJC-1295 & Ipamorelin Blend was designed to address both major regulatory pathways simultaneously.

The Dual-Pathway Principle:

Why Dual-Pathway Research Matters:

• GHRH receptor activation increases growth hormone synthesis and primes somatotrophs

• GHSR activation amplifies the amplitude of growth hormone pulses

• Combined activation may produce different signaling profiles than either pathway alone

• Studying both pathways simultaneously provides a more complete picture of growth hormone axis regulation

Comparing Single vs. Combined Pathway Activation:

CJC-1295 vs. Modified GRF (1-29): Understanding the Difference

Researchers often encounter both CJC-1295 and Modified GRF (1-29) (sometimes called CJC-1295 no DAC). Understanding the distinction is important for experimental design.

The version included in this blend is the standard CJC-1295 formulation. Researchers should verify which analog is appropriate for their specific experimental design.

Chemical and Physical Properties

Molecular Characteristics of Each Component

Physical Form and Storage

The product is supplied as a lyophilized (freeze-dried) powder within a sterile, sealed vial. The blend appears as a white to off-white homogeneous powder. CJC-1295 & Ipamorelin Blend

Recommended Storage Conditions:

• Store lyophilized powder at -20°C (-4°F) or below for long-term preservation

• Protect from light exposure

• Keep desiccated to prevent moisture absorption

• Allow vial to reach room temperature before opening to avoid condensation

• Avoid repeated freeze-thaw cycles once reconstituted

Stability Considerations:
Both CJC-1295 and Ipamorelin are stable when stored properly in lyophilized form. The presence of D-amino acids in Ipamorelin enhances its resistance to enzymatic degradation. CJC-1295 & Ipamorelin Blend

Once reconstituted with an appropriate sterile solvent, the solution should be used promptly according to laboratory protocols.

Intended Use and Regulatory Status

Research Use Only

The CJC-1295 & Ipamorelin Blend is classified as a research chemical and is intended exclusively for laboratory and in vitro experimentation. This designation means the product is sold strictly for:

• In vitro testing — experiments conducted in controlled laboratory environments

• Cell culture studies — investigating pituitary somatotroph function

• Receptor binding assays — studying GHRHR and GHSR interactions

• Growth hormone axis research — investigating dual-pathway regulation

• Analytical research — chemical analysis and characterization studies

• Scientific investigation — basic research into peptide structure and function

Important Regulatory Notice

This product is not a drug, food, cosmetic, or medical device. Bodily introduction of any kind into humans or animals is strictly forbidden by law. The product should only be handled by licensed, qualified professionals working in appropriate laboratory facilities.

The supplier is a chemical supplier, not a compounding pharmacy or outsourcing facility under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. All product information provided is for educational purposes only and does not constitute medical advice or clinical recommendations. CJC-1295 & Ipamorelin Blend

Handling and Safety Guidelines

Professional Handling Required

The CJC-1295 & Ipamorelin Blend should only be handled by trained laboratory personnel wearing appropriate personal protective equipment (PPE), including:

• Laboratory coat

• Nitrile gloves

• Safety goggles or face shield

• Appropriate respiratory protection if aerosolization is possible

Reconstitution Protocol

For laboratory use, the lyophilized powder should be reconstituted with a sterile, compatible solvent. Standard practice includes:

1. Allow the sealed vial to reach room temperature — approximately 15-30 minutes

2. Clean the rubber stopper with an alcohol swab

3. Add the calculated volume of solvent to achieve desired concentration

4. Gently swirl or roll the vial between palms — do not shake vigorously to avoid foaming

5. Allow complete dissolution before use — this typically takes 5-10 minutes

Reconstitution Example for the Blend (5mg/5mg = 10mg total):
For researchers needing a 5mg/mL total concentration (2.5mg/mL each), add 2mL of sterile solvent. For a 10mg/mL total concentration (5mg/mL each), add 1mL of solvent. For a 2mg/mL total concentration (1mg/mL each), add 5mL of solvent. Always verify calculations based on specific experimental requirements. CJC-1295 & Ipamorelin Blend

Solvent Considerations:
Both peptides are water-soluble. Researchers should determine the appropriate solvent based on their specific experimental protocol. Common options include sterile water for injection, bacteriostatic water, or buffered solutions such as phosphate-buffered saline (PBS) at neutral pH.

Disposal Considerations

Dispose of the blend and any contaminated materials in accordance with federal, state, and local regulations for chemical waste disposal. Do not dispose of in regular trash or down drains unless permitted by local guidelines. CJC-1295 & Ipamorelin Blend

Research Applications

The CJC-1295 & Ipamorelin Blend is used in various laboratory research contexts, primarily focused on growth hormone axis regulation and pituitary cell biology. Typical applications include:

GHRHR and GHSR Dual-Pathway Studies:
The primary research interest in this blend revolves around the simultaneous activation of both major growth hormone regulatory pathways. Researchers use the blend to study:

• GHRHR and GHSR signaling interactions

• Synergistic effects on growth hormone secretion

• Receptor crosstalk and signal integration

• Comparative signaling profiles of single vs. dual pathway activation

Pituitary Cell Culture Studies:
Researchers use the blend in controlled pituitary cell culture systems to investigate:

• Somatotroph function and responsiveness

• Growth hormone synthesis and secretion dynamics

• Pituitary cell signaling pathways

• Receptor regulation and desensitization

Growth Hormone Pulse Dynamics Research:
The complementary mechanisms of CJC-1295 (increasing baseline secretion) and Ipamorelin (amplifying pulse amplitude) allow researchers to study:

• Growth hormone pulse generation mechanisms

• Factors affecting pulse amplitude and frequency

• Hypothalamic-pituitary integration

• Feedback regulation of the growth hormone axis

GPCR Signaling Research:
Both CJC-1295 (via GHRHR) and Ipamorelin (via GHSR) activate distinct GPCRs. The blend serves as a research tool for:

• Comparing Gs (GHRHR) and Gq (GHSR) signaling pathways

• Studying receptor cross-talk in the same cell type

• GPCR signaling integration and convergence

• Downstream effector activation (cAMP, IP3, calcium)

In Vitro Efficacy Studies:
Researchers use the blend to study:

• Concentration-response relationships for growth hormone release

• Time-course of receptor activation and signaling

• Synergistic effects of dual-pathway activation

• Receptor selectivity and specificity

Comparative Mechanism Research:
The blend allows investigators to compare:

• Effects of GHRHR activation vs. GHSR activation

• Single-pathway vs. dual-pathway signaling outcomes

• Different growth hormone secretagogue classes

Researchers should design their experimental protocols based on peer-reviewed literature and established laboratory practices specific to growth hormone secretagogues. CJC-1295 & Ipamorelin Blend

What Makes This Product Different

Pre-Formulated Dual-Pathway Blend

Unlike individual research peptides that require separate handling, reconstitution, and combination, this blend combines two complementary growth hormone secretagogues into a single vial at an optimal 1:1 ratio. This structured approach supports consistency, efficiency, and reproducibility in research settings.

Complementary Mechanisms

The blend combines a GHRH analog (CJC-1295) with a GHSR agonist (Ipamorelin), targeting both major pathways that regulate growth hormone secretion. This dual-pathway approach allows researchers to study the integrated regulation of the growth hormone axis.

Synergistic Research Potential

The combination of CJC-1295 and Ipamorelin allows researchers to study potential synergistic effects that cannot be observed with either peptide alone. The blend addresses both growth hormone synthesis (via GHRHR) and pulse amplitude modulation (via GHSR).

Optimal 1:1 Ratio

The 5mg/5mg (1:1) ratio reflects the different effective concentration ranges of each peptide, providing researchers with a balanced formulation for dual-pathway studies. CJC-1295 & Ipamorelin Blend

Rigorous Quality Control

Unlike research chemicals sold without verification, this blend comes with documented third-party testing for every batch. This commitment to quality assurance gives researchers confidence in the consistency and reliability of their experimental results.

Complete Documentation

Each product listing includes full chemical specifications and component quantities. This transparency allows researchers to verify the exact formulation they are working with.

Appropriate Packaging for Research Use

The sterile, sealed vial packaging protects the lyophilized powder from environmental contaminants. The 5mg/5mg blend provides researchers with a standardized formulation for reproducible experimentation. CJC-1295 & Ipamorelin Blend

Batch Traceability

Each package of the blend includes batch identification numbers that allow researchers to trace their material back to original manufacturing and testing records. This traceability is essential for reproducible research and quality documentation.

Frequently Asked Questions for Researchers

What is the purity level of the blend?

Each batch is tested to verify purity exceeding 99% for both components. Individual certificates of analysis are available upon request.

How should the lyophilized powder be stored?

Store at -20°C or below, protected from light and moisture. Avoid repeated freeze-thaw cycles once reconstituted.

What solvent should be used for reconstitution?

Both peptides are water-soluble. Researchers should determine the appropriate solvent based on their specific experimental protocol. Common options include sterile water for injection, bacteriostatic water, or buffered solutions such as PBS at neutral pH.

Is this product sterile?

The lyophilized powder is manufactured under aseptic conditions, but researchers should follow standard laboratory practices for handling research chemicals. For cell culture applications, additional filtration using a 0.22-micron filter may be appropriate.

What is the ratio of CJC-1295 to Ipamorelin in this blend?

The blend contains a 1:1 ratio — 5mg of CJC-1295 and 5mg of Ipamorelin per vial (total 10mg).

How does this blend differ from using the peptides separately?

The pre-formulated blend ensures consistent 1:1 ratios across experiments and simplifies handling. For research requiring independent dose variation, separate vials may be preferred.

What is the difference between CJC-1295 and Modified GRF (1-29)?

CJC-1295 includes a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life. Modified GRF (1-29) lacks this modification and has a shorter half-life. The version in this blend is CJC-1295 with DAC.

Why combine CJC-1295 and Ipamorelin?

They target complementary pathways: CJC-1295 activates GHRH receptors (increasing GH synthesis and baseline pulsatile release), while Ipamorelin activates GHSR (amplifying GH pulse amplitude). Combined activation may produce different signaling profiles than either pathway alone.

Can this blend be used in combination with other research reagents?

Researchers should determine compatibility based on their specific experimental design. Standard laboratory practice includes testing interactions in control experiments before full-scale implementation.

Final Notes for Laboratory Researchers

The CJC-1295 & Ipamorelin Blend represents a high-purity research tool for qualified professionals conducting legitimate scientific investigations into growth hormone axis regulation, GHRHR and GHSR signaling, pituitary somatotroph function, and related endocrinological fields. With documented third-party testing, complete chemical specifications, and appropriate packaging for laboratory use, this product meets the standards expected by serious researchers.

The pre-formulated 1:1 blend offers researchers the ability to study dual-pathway growth hormone regulation simultaneously, including GHRH receptor activation (CJC-1295) and GHSR activation (Ipamorelin), providing a more complete picture of growth hormone axis regulation than either pathway alone.

For research use only. Not for human or animal consumption. Handle only in appropriate laboratory facilities with proper safety equipment and training.